Skip to main content

Table 1 Demographics of IIM participant

From: Muscle B mode ultrasound and shear-wave elastography in idiopathic inflammatory myopathies (SWIM): criterion validation against MRI and muscle biopsy findings in an incident patient cohort

Participant

Symptom duration

Time since diagnosis

Age

Sex

Diagnosis

Myositis specific antibodies

CK level

MMT Deltoid/10

MMT Vastus Lateralis/10

Medications at the time of US

Echo deltoid (1–4)

Echo vastus lateralis (1–4)

PD Deltoid (0–4)

PD vastus lateralis (0–4)

MRI deltoid

MRI vastus lateralis

Muscle biopsy deltoid

Muscle biopsy vastus lateralis

1

< 1 yr

< 1 mth

30

F

NAM

Seronegative

9350

9

9

Prednisolone, methotrexate

1

2

1

1

Oedema

N/A

N/A

N/A

2

< 1 mth

< 1 mth

54

F

NAM

Anti-HMGCR

9390

8

9

Prednisolone, methotrexate

2

2

0

0

N/A

Oedema

N/A

N/A

3

< 6 mth

< 1 mth

66

F

NAM

Seronegative

10,600

9

10

Nil

2

3

0

0

N/A

Fatty infiltration

N/A

Atrophy

4

< 1 yr

< 6 mth

79

F

DM

Anti-OJ, Anti-NXP2

553

9

9

Nil

1

2

0

1

N/A

N/A

N/A

Fatty infiltration

5

< 5 yrs

< 1 mth

70

F

IBM

Seronegative

N/A

9

9

Nil

2

3

0

1

N/A

Atrophy, fatty infiltration

N/A

N/A

6

≥ 5 yrs

< 1 mth

60

F

OM

Anti-Ro-52, Anti-NXP2

N/A

10

8

Nil

2

3

2

0

N/A

Oedema

N/A

Inflammation, fibrosis, fatty infiltration

7

< 5 yrs

< 1 mth

74

M

IBM

Seronegative

359

10

N/A

Nil

1

2

0

1

N/A

N/A

N/A

N/A

8

< 1 mth

< 1 mth

20

M

DM

Anti-Mi2a

14,900

1

3

Prednisolone

1

2

3

0

N/A

Oedema

N/A

Inflammation, fibrosis, fatty infiltration

9

≥ 5 yrs

< 1 yr

60

M

DM

Anti-Ro-52, Anti-NXP2

6410

1

1

Prednisolone, mycophenolate

1

1

1

2

N/A

Oedema, fatty infiltration

N/A

N/A

10

< 5 yrs

< 6 mths

70

M

IBM

Seronegative

N/A

10

8

Nil

1

4

0

0

N/A

N/A

N/A

Inflammation, fibrosis, fatty infiltration

11

< 5 yrs

< 1 mth

63

M

IBM

Anti-CN1A

261

10

2

Nil

1

3

2

0

N/A

N/A

N/A

Inflammation, fibrosis, fatty infiltration

12

< 1 yr

< 6 mths

65

M

IBM

Seronegative

1070

10

9

Nil

2

3

0

0

N/A

Oedema, fatty infiltration

N/A

Inflammation, fibrosis, fatty infiltration

13

< 1 yr

< 1 mth

26

F

DM

Anti-NXP2

287

8

9

Prednisolone, methotrexate

1

2

1

0

N/A

Oedema

N/A

Inflammation

14

≥ 5 yrs

< 1 mth

69

M

NAM

Anti-SRP

436

10

8

Nil

1

2

1

2

N/A

N/A

N/A

N/A

15

≥ 5 yrs

< 6 mth

70

M

IBM

Seronegative

69

10

10

Nil

1

1

1

1

N/A

Normal

Normal

N/A

16

< 1 yr

< 1 mth

65

F

NAM

Seronegative

11

10

9

Prednisolone, mycophenolate

3

3

0

0

N/A

Oedema, fatty infiltration

N/A

Inflammation, fatty infiltration

17

< 1 yr

< 1 mth

33

F

NAM

Seronegative

4010

9

7

Prednisolone, hydroxychloroquine, mycophenolate

3

3

0

1

Oedema, atrophy

N/A

Inflammation, fibrosis, fatty infiltration

N/A

18

< 1 yr–< 5 yrs

< 6 mth

54

F

DM

Seronegative

19

10

5

Mycophenolate, prednisolone, IVIG

2

2

0

0

N/A

Oedema

N/A

Fatty infiltration and fibrosis

19

< 6 mth

< 6 mth

61

M

NAM

Anti -HMGCR

19,000

8

5

Prednisolone, methotrexate

1

3

0

0

Oedema

Oedema

N/A

Inflammation, fibrosis, fatty infiltration

20

≥ 5 yrs

< 1 mth

79

F

DM

Anti-SAE

87

9

7

Nil

3

3

1

1

N/A

Atrophy, fatty infiltration

N/A

Inflammation, fibrosis, fatty infiltration

Median/SD

–

–

64/17

–

–

–

553/3

10

8

–

1/1

3/1

0/1

0/1

–

–

–

–

  1. NAM: Necrotising autoimmune myopathy, DM: dermatomyositis, IBM: inclusion body myositis, OM: overlap myositis, CK: creatinine kinase, MMT: manual muscle testing, PD: power Doppler, MRI: magnetic resonance imaging, mths: months, yrs: years, N/A: not available. SD: standard deviation, Echo; echogenicity
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us